Risk factors associated with Retinopathy of Prematurity development and progression

Ramírez, N. de las Rivas; Aranda, G. Luque; Díaz, Francisca Rius; Frías, Francisco Javier Pérez; Tamayo, Tomás Sánchez

doi:10.1038/s41598-022-26229-4

Cited by 19 publications

(10 citation statements)

References 39 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RDS in preterm infants typically progresses over the first two–three days of life and resolves by one week of age with an increased production of endogenous surfactant [ 253 ]. Preterm infants with RDS often require mechanical ventilation and supplemental oxygen, both of which are widely recognized risk factors for ROP [ 1 , 254 , 255 , 256 , 257 , 258 , 259 ]. In addition, the alternation in cytokines of neonates with RDS compared to non-RDS counterparts may also take part.…”

Section: Correlation With Other Maternal or Neonatal Diseasesmentioning

confidence: 99%

Systemic Cytokines in Retinopathy of Prematurity

Lien

et al. 2023

JPM

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP), a vasoproliferative vitreoretinal disorder, is the leading cause of childhood blindness worldwide. Although angiogenic pathways have been the main focus, cytokine-mediated inflammation is also involved in ROP etiology. Herein, we illustrate the characteristics and actions of all cytokines involved in ROP pathogenesis. The two-phase (vaso-obliteration followed by vasoproliferation) theory outlines the evaluation of cytokines in a time-dependent manner. Levels of cytokines may even differ between the blood and the vitreous. Data from animal models of oxygen-induced retinopathy are also valuable. Although conventional cryotherapy and laser photocoagulation are well established and anti-vascular endothelial growth factor agents are available, less destructive novel therapeutics that can precisely target the signaling pathways are required. Linking the cytokines involved in ROP to other maternal and neonatal diseases and conditions provides insights into the management of ROP. Suppressing disordered retinal angiogenesis via the modulation of hypoxia-inducible factor, supplementation of insulin-like growth factor (IGF)-1/IGF-binding protein 3 complex, erythropoietin, and its derivatives, polyunsaturated fatty acids, and inhibition of secretogranin III have attracted the attention of researchers. Recently, gut microbiota modulation, non-coding RNAs, and gene therapies have shown promise in regulating ROP. These emerging therapeutics can be used to treat preterm infants with ROP.

show abstract

Section: Correlation With Other Maternal or Neonatal Diseasesmentioning

confidence: 99%

Systemic Cytokines in Retinopathy of Prematurity

Lien

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…Other risk factors, such as poor weight gain, multiple pregnancies, oxygen concentration, hypoxia, respiratory distress syndrome, blood transfusions, anaemia, degree of intraventricular haemorrhage, sepsis, etc. have also been described 4–7 …”

mentioning

confidence: 94%

“…have also been described. [4][5][6][7] ROP occurs because of the abnormal development of retinal blood vessels and may result in impaired vision and even retinal detachment which can lead to blindness. Retinal blood vessels grow outwards from the optic disc towards the periphery with the nasal side fully vascularized by 32-36 weeks gestation and the temporal side by 40 weeks.…”

mentioning

confidence: 99%

Analysis of trends in retinopathy of prematurity over 5 years in a tertiary neonatal intensive care unit

Thu,

Tauro,

Russell

et al. 2023

J Paediatrics Child Health

View full text Add to dashboard Cite

AimThe aim of the study was to look at the incidence and trend of retinopathy of prematurity (ROP) between 2017 and 2021 in a tertiary neonatal intensive care unit (NICU) in Australia and to compare potential modifiable risk factors of ROP between preterm infants who required treatment for ROP and who did not need treatment.MethodsThis retrospective study used the data of newborn infants who were <31 weeks gestational age (GA) or birth weight (BW) of <1250 g born between 2017 and 2021 at a tertiary NICU in Australia (n = 261). Univariate analysis using t test for continuous data, Fischer exact test for categorical data and multiple logistic regression analysis were undertaken to identify any significant differences between two groups.ResultsA total number of 261 infants were studied. 55.9% of infants developed any type of ROP (146 infants out of 261 infants), type 1 ROP was 5.4% (14 out of 261) and aggressive ROP (AROP) was 3% (8 out of 261). Out of 146 infants who were diagnosed with ROP, 22 (15%) of them required treatment. Mean GA for those who underwent ROP treatment was 25.6 (±1.47) weeks and for those who did not require treatment was 27.6 (±1.95) weeks. The mean BWs for those who needed treatment was 764 (±189.32) g and for those who did not need treatment was 1039 (±306.06) g. The mean duration of invasive ventilation for infants with ROP requiring treatment and those who did not require treatment were 23.95 (±22.41) days and 9.89 (±17.2) days. The total duration of oxygen requirement was 235.54 (±160.5) days and 121.11 (±117.34) days for those who needed treatment and those who did not need treatment respectively. Among infants who required treatment for ROP, 68.18% required blood transfusion whereas among those who did not need treatment, 24.19% required blood transfusion.ConclusionLower GA, lower BW, longer duration of invasive ventilation, longer total duration of oxygen requirement and blood transfusion in first 2 weeks of life were significant in preterm infants who required treatment for ROP compared with those who did not.

show abstract

“…However, the formation of blood from new blood vessels from pre-existing one (angiogenesis) is a critical physiological process for growth and development, also it›s vital for wound healing and granulation tissue formation [4,5], but unfortunately, tumors utilize this process, angiogenesis, to «transform» from benign to a malignant state. Thus, angiogenesis inhibitors are widely applied for the conflict of cancers [6].…”

Section: Introductionmentioning

confidence: 99%

VEGF Gene Expression and Angiogenesis in the Chorioallantoic Membrane: the Role of Cloprostenol

Abdullah

shindala

Mustafa

2023

Egyptian Journal of Veterinary Sciences

View full text Add to dashboard Cite

B ACKGROUND: Cloprostenol, as a common clinically used PGF 2 α analogue, is widely employed in veterinary practice to induce parturition. It is main action, as a potent luteolytic, carried by vasoconstriction of the blood vessels that supply the corpus luteum. While vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis. Objective: This study aimed to investigate the precise effects of PGF 2 α analogue (cloprostenol) on the VEGF gene expression. Methods: Chorioallantoic membranes (CAM) of local chicken fertilized eggs were used at 6 and 9 days of incubation. The control group, without treatment, and other groups treated with (22.5µg/egg) of cloprostenol sodium (Galapan) ® and eggs were re-incubated. CAM blood vessels were observed and documented and samples of them were isolated at 1, 2, 4, 6, 12, and 24 hours after incubation. mRNA was isolated and converted to cDNA, and RT-PCR was done to determine the gene expression of VEGF. Results: It shows that the peak of gene expression of VEGF gene was at 24 hours of day 9 of incubation. Furthermore, the best antiangiogenic effects were at the same time of 6 hours of day 6 of incubation. Conclusion: It could be concluded that PGF 2 α analogue (cloprostenol) has vasoactive properties depend particularly on the VEGF, this action is in a time-dependent manner and may be based on the hypoxia-induced pathways that elicited by vasoconstrictive action of cloprostenol.

show abstract

Risk factors associated with Retinopathy of Prematurity development and progression

Cited by 19 publications

References 39 publications

Systemic Cytokines in Retinopathy of Prematurity

Systemic Cytokines in Retinopathy of Prematurity

Analysis of trends in retinopathy of prematurity over 5 years in a tertiary neonatal intensive care unit

VEGF Gene Expression and Angiogenesis in the Chorioallantoic Membrane: the Role of Cloprostenol

Contact Info

Product

Resources

About